Premium
Factors affecting response to biologic treatment in psoriasis
Author(s) -
Karczewski Jacek,
Poniedziałek Barbara,
Rzymski Piotr,
Adamski Zygmunt
Publication year - 2014
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12160
Subject(s) - psoriasis , medicine , disease , population , dermatology , affect (linguistics) , biologic agents , immune system , intensive care medicine , immunology , environmental health , linguistics , philosophy
Psoriasis is a chronic, immune‐mediated inflammatory skin disease, affecting approximately 2–4% of the population in western countries. Patients with a more severe form of the disease are typically considered for systemic therapy, including biologics. In spite of the overall superiority of biologic agents, the treatment response may differ substantially among individual patients. As with other medical conditions, a range of factors contribute to response heterogeneity observed in psoriasis. Proper identification of these factors can significantly improve the therapeutic decisions. This review focuses on potential genetic and nongenetic factors that may affect the treatment response and outcomes in patients with psoriasis.